CJC-1295 Without DAC Peptide USA | Buy CJC-1295 Without DAC | Research-Grade Peptide ≥99% Purity

CJC-1295 Without DAC (Modified GRF 1-29) is a synthetic modified analogue of Growth Hormone-Releasing Hormone representing the stabilised 29-amino acid active fragment of GHRH, studied extensively across endocrinology, growth hormone axis research, pituitary biology, and metabolic science for its selective and physiologically pulsatile stimulation of pituitary growth hormone secretion via GHRH receptor activation — making it one of the most widely used and pharmacologically precise GHRH analogue research compounds in modern growth hormone biology. Researchers and institutions across the USA can source verified, research-grade CJC-1295 Without DAC with fast domestic dispatch and full batch documentation included.

✅ ≥99% Purity — HPLC & Mass Spectrometry Verified

✅ Batch-Specific Certificate of Analysis (CoA) Included

✅ Sterile Lyophilised Powder | GMP Manufactured

✅ Fast Dispatch Across the USA | USA Peptides In Stock

What Is CJC-1295 Without DAC?

CJC-1295 Without DAC — also commonly referred to as Modified GRF 1-29 or Mod GRF 1-29 — is a synthetic 29-amino acid GHRH analogue derived from the biologically active N-terminal fragment of endogenous Growth Hormone-Releasing Hormone (GHRH 1-29), with four strategic amino acid substitutions introduced to significantly enhance its stability and resistance to enzymatic degradation compared to both native GHRH and the shorter-acting Sermorelin.

The four amino acid modifications in CJC-1295 Without DAC are specifically positioned to protect the peptide against the primary enzymatic cleavage sites that rapidly degrade native GHRH and Sermorelin in biological systems — extending CJC-1295 Without DAC’s half-life to approximately 30 minutes compared to Sermorelin’s 10–20 minutes, while preserving full GHRH receptor binding activity and physiological GH stimulation characteristics. These targeted substitutions represent a significant advancement in GHRH analogue research tool design, providing a meaningful stability improvement without the extreme half-life extension that the DAC modification introduces.

The critical distinction between CJC-1295 Without DAC and CJC-1295 With DAC lies in the Drug Affinity Complex — a reactive lysine modification present in the With DAC form that enables covalent albumin binding in the bloodstream, extending half-life to approximately seven days. CJC-1295 Without DAC lacks this modification entirely, producing a half-life of approximately 30 minutes and a GH release profile that closely mirrors the physiological pulsatile pattern of endogenous GHRH-driven GH secretion — making it the preferred GHRH analogue for research designs where physiological GH pulse dynamics are important.

CJC-1295 Without DAC acts by binding to the GHRH receptor (GHRH-R) on anterior pituitary somatotroph cells, activating the cAMP-PKA intracellular signalling cascade that drives GH gene expression and pulsatile GH secretion — the same receptor and signalling pathway activated by endogenous GHRH, but with the improved enzymatic stability that makes CJC-1295 Without DAC a more practical and reproducible research tool than native GHRH or Sermorelin for most laboratory applications.

CJC-1295 Without DAC is one of the most widely used GHRH analogue research compounds available to buy in the USA, with active demand across endocrinology, GH axis biology, metabolic research, and pituitary science programs at research institutions nationwide — and is particularly widely studied in combination with Ipamorelin for dual-pathway GH secretion research.

What Does CJC-1295 Without DAC Do in Research?

In controlled pre-clinical and laboratory settings, CJC-1295 Without DAC has been studied across a wide range of endocrinological, metabolic, and physiological research applications:

Growth Hormone Secretion Research CJC-1295 Without DAC’s primary research application is its stimulation of pulsatile GH release from anterior pituitary somatotrophs via GHRH-R activation. Studies have examined its GH-stimulating characteristics, dose-response relationships, GH pulse dynamics, and how its enhanced enzymatic stability compared to Sermorelin affects research reproducibility and GH stimulation consistency across experimental protocols.

GHRH Receptor Pharmacology Research CJC-1295 Without DAC is used as a stabilised GHRH-R agonist in receptor binding and activation assays, enabling researchers to study GHRH receptor pharmacology with improved experimental consistency compared to shorter-acting native GHRH or Sermorelin. Research has examined its receptor binding kinetics, cAMP-PKA signalling activation, and how the four amino acid modifications affect receptor interaction compared to the native GHRH sequence.

Pulsatile GH Release Research CJC-1295 Without DAC’s approximately 30-minute half-life produces a GH release profile that more closely mirrors physiological GHRH-driven GH pulsatility than longer-acting compounds. Research has examined how this pulsatile profile differs from the sustained GH elevation produced by CJC-1295 With DAC — providing direct insight into the physiological versus pharmacological GH secretion patterns and their downstream biological consequences.

Hypothalamic-Pituitary-Somatotropic Axis Research CJC-1295 Without DAC is used to probe the hypothalamic-pituitary-somatotropic axis, studying how GHRH-R stimulation interacts with somatostatin inhibitory tone, GH feedback regulation, and pituitary somatotroph responsiveness — with its moderate half-life providing a practical balance between research reproducibility and physiological accuracy.

IGF-1 Axis Research GH released in response to CJC-1295 Without DAC stimulates hepatic IGF-1 production. Studies have examined the downstream IGF-1 signalling cascade — including IGF-1R activation, anabolic tissue responses, and metabolic effects — using CJC-1295 Without DAC as the upstream GHRH-R trigger to study the complete GHRH — GH — IGF-1 signalling axis from receptor activation to end-organ response.

Dual-Pathway Combination Research CJC-1295 Without DAC is most widely studied in combination with Ipamorelin — a selective GHSR-1a ghrelin receptor agonist — to examine the synergistic GH release produced by simultaneous activation of both primary pituitary GH release pathways. Research has documented that GHRH-R and GHSR-1a co-stimulation produces GH output substantially greater than either pathway alone, making the CJC-1295 Without DAC + Ipamorelin combination one of the most actively researched GH secretagogue protocols in endocrinology science.

GHRH Analogue Comparison Research CJC-1295 Without DAC is used in comparative GHRH pharmacology studies alongside Sermorelin (shorter half-life, fewer modifications), Tesamorelin (full-length GHRH 1-44 analogue), and CJC-1295 With DAC (albumin-binding long-acting form) — allowing researchers to directly examine how structural modifications and half-life differences across the GHRH analogue class affect GH stimulation profiles, receptor pharmacology, and downstream biological outcomes.

Body Composition Research Pre-clinical studies have examined how GHRH-R-driven GH secretion via CJC-1295 Without DAC influences body composition parameters including lean mass accretion, fat mass distribution, and metabolic rate in animal models — contributing to research on how pulsatile pituitary-derived GH affects body composition biology compared to exogenous GH administration.

Metabolic Research Studies have examined CJC-1295 Without DAC’s downstream metabolic effects in pre-clinical models — including its influence on lipid metabolism, glucose homeostasis, insulin sensitivity, and energy expenditure — reflecting the broad metabolic role of the GHRH-GH-IGF-1 axis and research interest in how physiologically pulsatile pituitary GH stimulation affects systemic metabolic regulation.

Ageing and Somatopause Research Research has examined CJC-1295 Without DAC in aged animal models with reduced somatotropic axis activity, exploring how stabilised GHRH-R stimulation affects GH pulse characteristics, IGF-1 levels, and metabolic parameters — contributing to the broader field of somatopause research and age-related GH decline biology.

All applications are for research purposes only. CJC-1295 Without DAC as supplied is not intended for human therapeutic use.

What Do Studies Say About CJC-1295 Without DAC?

CJC-1295 Without DAC has accumulated a well-established research profile across endocrinology, pituitary biology, and GH axis science:

Enzymatic Stability: Research has characterised the four amino acid substitutions in CJC-1295 Without DAC and their protective effect against enzymatic degradation at primary cleavage sites — confirming significantly enhanced stability compared to native GHRH and Sermorelin while maintaining full GHRH-R binding and activation activity, establishing it as a more reproducible and experimentally consistent GHRH research tool.

Pulsatile GH Release: Studies have documented CJC-1295 Without DAC’s ability to stimulate physiologically pulsatile GH release in pre-clinical models — with research confirming that its approximately 30-minute half-life produces a GH pulse profile that mirrors endogenous GHRH-driven secretion more closely than longer-acting analogues, making it the preferred GHRH compound when physiological GH pulse dynamics are a research priority.

GHRH-R Pharmacology: Research has characterised CJC-1295 Without DAC’s receptor binding profile at GHRH-R, documenting its binding affinity, cAMP signalling activation kinetics, and how the four amino acid modifications affect receptor interaction compared to the native sequence — providing pharmacological insight into how targeted structural stabilisation affects GHRH analogue receptor activity.

Dual-Pathway Synergy: Studies examining CJC-1295 Without DAC in combination with Ipamorelin have consistently documented synergistic GH release when both GHRH-R and GHSR-1a are co-stimulated simultaneously — establishing the pharmacological rationale for dual-pathway combination research and confirming that CJC-1295 Without DAC’s pulsatile profile combines effectively with Ipamorelin’s GHSR-1a activity.

Comparison With DAC Form: Research directly comparing CJC-1295 Without DAC and CJC-1295 With DAC has documented the distinct GH release profiles produced by each — with Without DAC producing pulsatile GH secretion and With DAC producing sustained GH elevation — providing direct insight into how GHRH analogue half-life affects GH secretion quality and the suitability of each form for different research designs.

IGF-1 and Downstream Effects: Research has documented corresponding IGF-1 increases following CJC-1295 Without DAC-driven GH stimulation in pre-clinical models, with downstream anabolic and metabolic effects confirmed across multiple tissue types — establishing its utility as a tool for studying the complete pulsatile GHRH-GH-IGF-1 signalling cascade.

CJC-1295 Without DAC vs Related GHRH and GH Research Compounds

Feature	CJC-1295 No DAC	CJC-1295 With DAC	Sermorelin	Tesamorelin	HGH 191AA
Type	Modified GHRH analogue (1-29)	Modified GHRH analogue + albumin binding	GHRH analogue (1-29)	Full-length GHRH analogue (1-44)	Recombinant GH protein
Amino Acid Modifications	4 stabilising substitutions	4 substitutions + DAC	None	N-terminal trans-3-hexenoic acid	N/A
Half-Life	~30 minutes	~7 days	~10–20 minutes	~25–40 minutes	~20–30 minutes
GH Release Profile	Pulsatile — physiologically mimicking	Sustained — prolonged GH elevation	Acute pulsatile	Pulsatile — moderate duration	Direct — bypasses pituitary
Receptor Target	GHRH-R	GHRH-R	GHRH-R	GHRH-R	GHR directly
Best For	Pulsatile GH studies / dual-pathway combination research	Sustained GHRH-R activation studies	Acute pituitary stimulation / GHRH-R pharmacology	Full-length GHRH / visceral fat research	Direct GHR signalling studies

Product Specifications

Parameter	Specification
Full Name	CJC-1295 Without DAC (Modified GRF 1-29 / Mod GRF 1-29)
Peptide Length	29 Amino Acids
Type	Modified synthetic GHRH analogue — 4 amino acid substitutions
Receptor Target	GHRH-R (Growth Hormone-Releasing Hormone Receptor)
Half-Life	~30 minutes
Purity	≥99% (HPLC & MS Verified)
Form	Sterile Lyophilised Powder
Solubility	Sterile water, bacteriostatic water, PBS
Storage (Powder)	-20°C, protect from light
Storage (Reconstituted)	2–8°C, use promptly
Manufacturing	GMP Manufactured

Buy CJC-1295 Without DAC in the USA — What’s Included

Every order includes full batch documentation:

✅ Batch-Specific Certificate of Analysis (CoA)

✅ HPLC Chromatogram

✅ Mass Spectrometry Confirmation

✅ Sterility & Endotoxin Testing Report

✅ Reconstitution Protocol

✅ Technical Research Support

Frequently Asked Questions — CJC-1295 Without DAC USA

Can I buy research-grade CJC-1295 Without DAC in the USA? Yes. We supply research-grade CJC-1295 Without DAC to researchers and institutions across the United States. All orders include full batch documentation and are packaged to maintain peptide integrity during transit. This compound is supplied strictly for laboratory research use only.

What is the difference between CJC-1295 Without DAC and CJC-1295 With DAC? The key difference is the Drug Affinity Complex (DAC) — a reactive lysine modification present in the With DAC form that enables the peptide to covalently bind albumin in the bloodstream, extending its half-life from approximately 30 minutes to approximately seven days. CJC-1295 Without DAC produces a physiologically pulsatile GH release profile with a half-life of around 30 minutes. CJC-1295 With DAC produces sustained, prolonged GH elevation lasting days. Researchers choose Without DAC when studying physiologically pulsatile GH secretion and acute GHRH-R pharmacology, and With DAC when sustained GHRH-R activation and prolonged GH elevation are required.

What is the difference between CJC-1295 Without DAC and Sermorelin? Both are 29-amino acid GHRH analogues targeting GHRH-R, but CJC-1295 Without DAC has four amino acid substitutions that protect it against enzymatic degradation at primary cleavage sites — giving it a half-life of approximately 30 minutes compared to Sermorelin’s 10–20 minutes. This enhanced stability makes CJC-1295 Without DAC a more reproducible and consistent research tool for most laboratory applications, while Sermorelin — as the unmodified GHRH 1-29 fragment — is preferred when studying the native GHRH sequence’s pharmacological profile without stabilising modifications.

Why is CJC-1295 Without DAC most commonly studied with Ipamorelin? CJC-1295 Without DAC activates GHRH-R while Ipamorelin activates GHSR-1a — the ghrelin receptor — on the same pituitary somatotroph cells. These are entirely independent and complementary GH release pathways that engage different intracellular signalling cascades. Research has consistently demonstrated that co-stimulating both pathways simultaneously produces synergistic GH output substantially greater than either compound alone. This pharmacological synergy, combined with Ipamorelin’s clean selectivity profile, makes CJC-1295 Without DAC + Ipamorelin the most widely studied dual-pathway GH secretagogue combination in endocrinology research.

What purity is required for CJC-1295 Without DAC research? ≥98% is considered research-grade, but ≥99% purity is strongly preferred for GHRH-R binding assays, GH secretion studies, pituitary biology research, and dual-pathway combination experiments where compound purity directly affects pharmacological accuracy. All CJC-1295 Without DAC supplied for USA researchers is independently verified to ≥99%.

How is CJC-1295 Without DAC reconstituted for lab use? Allow the vial to reach room temperature before opening. Add sterile water, bacteriostatic water, or PBS slowly down the vial wall and swirl gently — do not shake. CJC-1295 Without DAC is generally well soluble in aqueous solvents. Use promptly after reconstitution, or aliquot and store at -80°C to preserve peptide activity across multiple experimental uses. Avoid repeated freeze-thaw cycles.

Research Disclaimer

CJC-1295 Without DAC is supplied exclusively for legitimate scientific research purposes conducted within licensed laboratory environments. This product is not intended for human consumption, self-administration, or any therapeutic application. It must be handled by qualified researchers in compliance with applicable US federal and state regulations and institutional ethics guidelines. By purchasing, you confirm that this compound will be used solely for approved in-vitro or pre-clinical research purposes.